Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors
21 Septiembre 2023 - 7:00AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the appointment of Amir Jafri, President and CEO of Immunicom,
Inc., to its Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230921747791/en/
(Photo: Business Wire)
“Amir’s leadership track record speaks for itself,” said Jeff
Hawkins, CEO of Quantum-Si. “He has successfully managed businesses
across multiple industries and has built and led world class
R&D organizations responsible for advanced technology
development and the launch of over 50 products and technologies
globally. His experience with product development and his focus on
operational rigor will be an asset as we continue to expand the
company and break new ground in proteomics research.”
Mr. Jafri has more than 35 years of experience in biotech,
healthcare technology and devices, working in Fortune 20 companies
and his own startups. In 2013, he founded Immunicom, a medical
technology company focused on developing innovative,
non-pharmaceutical approaches for the treatment of cancer, and
inflammatory and autoimmune diseases. Previously, Mr. Jafri held
executive leadership positions at West Health, Cardinal Health and
the Manpower Group. Early in his career, he founded two healthcare
startups that were subsequently acquired. Currently, he serves on
the board of various healthcare technology startup companies and
nonprofit organizations. Mr. Jafri is an inventor on over 40
patents covering products and technologies across a range of
industries and applications. Mr. Jafri earned a Bachelor of Science
from Houston Christian University with a double major in Chemistry
and Biology and a minor in History.
“I am excited about Quantum-Si's pioneering work in
next-generation protein sequencing to enable broad-scale access to
proteomic data, for every scientist, everywhere,” said Mr. Jafri.
“My experience building and leading businesses that have developed
and successfully brought advanced technologies to market positions
me well to help guide the company through this next phase of its
evolution.”
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; our ongoing
leadership transition; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum™ protein
sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921747791/en/
Investors Jeff Keyes ir@quantum-si.com Media Anya
Bolshem media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Quantum Si (NASDAQ:QSI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024